This site is intended for Healthcare professionals only.
Elsevier-Clinicalkey

Cadila gets EIR from USFDA for Ahmedabad biologics unit


Cadila gets EIR from USFDA for Ahmedabad  biologics unit

NO OBSERVATION 

New Delhi: Drug firm Cadila Healthcare has recently announced that its biologics manufacturing facility at Ahmedabad has received Establishment Inspection Report(EIR) from the US health regulator with zero observations.

“The company’s biologics manufacturing facility located at the Zydus Biotech Park in Ahmedabad has received an EIR from the United States Food and Drug Administration (USFDA) signifying the successful closure of the audit,” Cadila Healthcare said in a filing to BSE.

The plant completed the USFDA audit from August 14-24 2018 with zero 483 observations, it added.

Read Also: Zydus Cadila gets USFDA nod for Desoximetasone cream



Source: PTI
0 comment(s) on Cadila gets EIR from USFDA for Ahmedabad biologics unit

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted